Cardiovascular Pathology
Volume 21, Issue 1 , Pages 17-27 , January 2012

Insulin-like growth factor-1 overexpression in cardiomyocytes diminishes ex vivo heart functional recovery after acute ischemia

  • Cecilia M. Prêle

      Affiliations

    • School of Anatomy and Human Biology, University of Western Australia, Crawley, Perth 6009
    • School of Biomedical and Chemical Sciences, University of Western Australia, Crawley, Perth 6009
    • Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, University of Western Australia, Nedlands WA 6009
    • C.M.P. and M.E.R. contributed equally to this work.
    • ,
  • Melissa E. Reichelt

      Affiliations

    • Heart Foundation Research Centre, Griffith University, QLD
    • Department of Physiology, University of Melbourne, Parkville, Victoria 3010
    • C.M.P. and M.E.R. contributed equally to this work.
    • ,
  • Steven E. Mutsaers

      Affiliations

    • Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, University of Western Australia, Nedlands WA 6009
    • PathWest Laboratory Medicine, WA
    • ,
  • Marilyn Davies

      Affiliations

    • School of Anatomy and Human Biology, University of Western Australia, Crawley, Perth 6009
    • ,
  • Lea M. Delbridge

      Affiliations

    • Department of Physiology, University of Melbourne, Parkville, Victoria 3010
    • ,
  • John P. Headrick

      Affiliations

    • Heart Foundation Research Centre, Griffith University, QLD
    • ,
  • Nadia Rosenthal

      Affiliations

    • European Molecular Biology Laboratory, Mouse Biology Unit, Monterotondo, Rome, Italy
    • ,
  • Marie A. Bogoyevitch

      Affiliations

    • Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, the University of Melbourne, Parkville, Victoria 3010
    • ,
  • Miranda D. Grounds

      Affiliations

    • School of Anatomy and Human Biology, University of Western Australia, Crawley, Perth 6009
    • Corresponding Author InformationCorresponding author. School of Anatomy & Human Biology, the University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. Tel.: +61 8 6488 7127; fax: +61 8 6488 10510.

Received 2 November 2009 ,Revised 29 July 2010 ,Accepted 30 November 2010.

References 

  1. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998;83:516–522
  2. Wang L, Ma W, Markovich R, Lee WL, Wang PH. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology. 1998;139:1354–1360
  3. Conti E, Andreotti F, Sciahbasi A, Riccardi P, Marra G, Menini E, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol. 2001;38:26–32
  4. Reiss K, Cheng W, Ferber A, Kajstura J, Li P, Li B, et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci U S A. 1996;93:8630–8635
  5. Reiss K, Cheng W, Pierzchalski P, Kodali S, Li B, Wang S, et al. Insulin-like growth factor-1 receptor and its ligand regulate the reentry of adult ventricular myocytes into the cell cycle. Exp Cell Res. 1997;235:198–209
  6. Ren J. Short-term administration of insulin-like growth factor I (IGF-1) does not induce myocardial IGF-1 resistance. Growth Horm IGF Res. 2002;12:162–168
  7. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol. 1999;31:2049–2061
  8. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A. 1995;92:8031–8035
  9. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest. 1995;95:619–627
  10. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 1997;100:1991–1999
  11. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262–267
  12. Donath MY, Sutsch G, Yan XW, Piva B, Brunner HP, Glatz Y, et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab. 1998;83:3177–3183
  13. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809–814
  14. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939–944
  15. Lee WL, Chen JW, Ting CT, Lin SJ, Wang PH. Changes of the insulin-like growth factor I system during acute myocardial infarction: implications on left ventricular remodeling. J Clin Endocrinol Metab. 1999;84:1575–1581
  16. Niebauer J, Pflaum CD, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol. 1998;32:393–397
  17. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003;139:642–648
  18. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50:637–642
  19. Yazdanpanah M, Rietveld I, Janssen JA, Njajou OT, Hofman A, Stijnen T, et al. An insulin-like growth factor-I promoter polymorphism is associated with increased mortality in subjects with myocardial infarction in an elderly Caucasian population. Am J Cardiol. 2006;97:1274–1276
  20. Yazdanpanah M, Sayed-Tabatabaei FA, Janssen JA, Rietveld I, Hofman A, Stijnen T, et al. IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. Eur J Endocrinol. 2006;155:751–756
  21. Shavlakadze T, Boswell JM, Burt DW, Asante EA, Tomas FM, Davies MJ, et al. Rskalpha-actin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: impact on regeneration, denervation and muscular dystrophy. Growth Horm IGF Res. 2006;16:157–173
  22. Matthews KG, Devlin GP, Stuart SP, Jensen JA, Doughty RN, Conaglen JV, et al. Intrapericardial IGF-I improves cardiac function in an ovine model of chronic heart failure. Heart Lung Circ. 2005;14:98–103
  23. Davani EY, Brumme Z, Singhera GK, Cote HC, Harrigan PR, Dorscheid DR. Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury. Crit Care. 2003;7:R176–R183
  24. Chao W, Matsui T, Novikov MS, Tao J, Li L, Liu H, et al. Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J Gene Med. 2003;5:277–286
  25. Santini MP, Tsao L, Monassier L, Theodoropoulos C, Carter J, Lara-Pezzi E, et al. Enhancing repair of the mammalian heart. Circ Res. 2007;100:1732–1740
  26. Palmen M, Daemen MJ, Bronsaer R, Dassen WR, Zandbergen HR, Kockx M, et al. Cardiac remodeling after myocardial infarction is impaired in IGF-1 deficient mice. Cardiovasc Res. 2001;50:516–524
  27. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res. 2004;94:514–524
  28. Shavlakadze T, Winn N, Rosenthal N, Grounds MD. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res. 2005;15:4–18
  29. Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol. 2003;547:247–254
  30. Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522:156–160
  31. Delaughter MC, Taffet GE, Fiorotto ML, Entman ML, Schwartz RJ. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 1999;13:1923–1929
  32. Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc Natl Acad Sci U S A. 1994;91:1686–1690
  33. Donath MY, Zierhut W, Gosteli-Peter MA, Hauri C, Froesch ER, Zapf J. Effects of IGF-I on cardiac growth and expression of mRNAs coding for cardiac proteins after induction of heart hypertrophy in the rat. Eur J Endocrinol. 1998;139:109–117
  34. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87:1715–1721
  35. Chew SL, Lavender P, Clark AJ, Ross RJ. An alternatively spliced human insulin-like growth factor-I transcript with hepatic tissue expression that diverts away from the mitogenic IBE1 peptide. Endocrinology. 1995;136:1939–1944
  36. Reiss K, Kajstura J, Zhang X, Li P, Szoke E, Olivetti G, et al. Acute myocardial infarction leads to upregulation of the IGF-1 autocrine system, DNA replication, and nuclear mitotic division in the remaining viable cardiac myocytes. Exp Cell Res. 1994;213:463–472
  37. Kotlyar AA, Vered Z, Goldberg I, Chouraqui P, Nas D, Fridman E, et al. Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine. Heart. 2001;86:693–700
  38. Infanger M, Faramarzi S, Grosse J, Kurth E, Ulbrich C, Bauer J, et al. Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc Pathol. 2007;16:291–299
  39. Headrick JP, Peart J, Hack B, Flood A, Matherne GP. Functional properties and responses to ischaemia–reperfusion in Langendorff perfused mouse heart. Exp Physiol. 2001;86:703–716
  40. Headrick JP, Peart J, Hack B, Garnham B, Matherne GP. 5′-Adenosine monophosphate and adenosine metabolism, and adenosine responses in mouse, rat and guinea pig heart. Comp Biochem Physiol A Mol Integr Physiol. 2001;130:615–631
  41. Peart J, Headrick JP. Intrinsic A(1) adenosine receptor activation during ischemia or reperfusion improves recovery in mouse hearts. Am J Physiol Heart Circ Physiol. 2000;279:H2166–H2175
  42. Peart J, Willems L, Headrick JP. Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine. Am J Physiol Heart Circ Physiol. 2003;284:H519–H527
  43. Reichelt ME, Willems L, Hack BA, Peart JN, Headrick JP. Cardiac and coronary function in the Langendorff-perfused mouse heart model. Exp Physiol. 2009;94:54–70
  44. Mutsaers SE, Foster ML, Chambers RC, Laurent GJ, McAnulty RJ. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol. 1998;18:611–619
  45. Mahdavi V, Chambers AP, Nadal-Ginard B. Cardiac alpha- and beta-myosin heavy chain genes are organized in tandem. Proc Natl Acad Sci U S A. 1984;81:2626–2630
  46. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991;266:24613–24620
  47. Horio T, Maki T, Kishimoto I, Tokudome T, Okumura H, Yoshihara F, et al. Production and autocrine/paracrine effects of endogenous insulin-like growth factor-1 in rat cardiac fibroblasts. Regul Pept. 2005;124:65–72
  48. Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, Cemerlang N, et al. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes. 2010;59:1512–1520
  49. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21:3–12
  50. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci. 2000;97:2809–2813
  51. Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation. 1997;96:1991–1998
  52. Willems L, Zatta A, Holmgren K, Ashton KJ, Headrick JP. Age-related changes in ischemic tolerance in male and female mouse hearts. J Mol Cell Cardiol. 2005;38:245–256
  53. Budas GR, Sukhodub A, Alessi DR, Jovanovic A. 3′Phosphoinositide-dependent kinase-1 is essential for ischemic preconditioning of the myocardium. FASEB J. 2006;20:2556–2558
  54. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, et al. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res. 2008;103:643–653

 This work was funded by an initial grant from the Muscular Dystrophy Association, USA (M.D.G., N.R.), with the assistance of a National Heart Foundation grant-in-aid (M.D.G. and M.A.B.), UWA Small Grant (C.M.P.), and bridging funding from the Australian Stem Cell Centre (M.D.G., M.A.B., and C.M.P.).

PII: S1054-8807(10)00193-6

doi: 10.1016/j.carpath.2010.11.008

Cardiovascular Pathology
Volume 21, Issue 1 , Pages 17-27 , January 2012

Article Tools

* Image Usage & Resolution